PSCI has conducted a materiality review for the sector every few years (2013, 2017, 2020). We are pleased to publish our latest assessment, this time applying a double materiality framework. The assessment is specifically focused on supply chains for the Pharmaceutical & Healthcare industries, and takes into account member views and a range of outside sources.

“New regulations and investor demands are raising the bar for company reporting on supply chain responsibility. This year's assessment highlights the growing importance of robust supply chain programs, encompassing a wider range of issues. It also reflects the changing nature of the industry’s products and markets, with biosafety joining the list for the first time and the issue of substandard and falsified medicines gaining prominence. Tackling climate change remains essential, as does responsible business practice against bribery and corruption. The PSCI Board uses this assessment as a control point to guide its own strategy. It can be a valuable resource for member companies comparing their own assessments and for those outside the sector to understand how supply chain risks are viewed within the industry. I hope you find it useful.” Dr. Deirdre O’Reilly Global EH&S Supplier Operations and Business Development Lead, Viatris & PSCI Chair

We encourage members, suppliers and our other stakeholders and invited to read the report and use it as an input to their own planning processes.

For anyone with comments to the report, please contact Rosie.Towe@Carnstone.com.